141pr cd38  (fluidigm)

Journal: The Journal of pathology

Article Title: APRIL/BAFF upregulation is associated with clonal B-cell expansion in Hunner-type interstitial cystitis.

doi: 10.1002/path.6353

Figure Lengend Snippet: Figure 1. Immune profiling of HIC-L, HIC-NL, and non-HIC samples. (A) Schematic illustration of HIC-L and HIC-NL biopsies. (B) Box plots showing the proportions of T lymphocytes, B lymphocytes, and plasma cells calculated by CIBERSORTx in HIC-L specimens (n = 37), patient- matched HIC-NL specimens (n = 37), and non-HIC specimens (n = 24). Asterisks indicate a significant difference (p < 0.05) (C) Hematoxylin and eosin staining of an FFPE section from a representative patient with HIC. (D) Images reconstructed from mass cytometry analysis of the FFPE section from the same patient. Each color indicates a different immune cell type. Blue represents unannotated cells. (E) Bar charts showing the proportion of isotypes (heavy chains) in each sample. Colored boxes in the upper panel indicate dominant isotypes. Within each dominant isotype, samples are arranged from the highest to the lowest proportion of the dominant isotype. BCG, Chr cys, and Follicular refer to BCG cystitis, chronic cystitis, and follicular cystitis, respectively. (F) Bar charts showing the proportion of isotypes (light chains) in each sample. Within each condition, samples are arranged from the highest to the lowest proportion of IgK. Dark brown and light brown boxes in the upper panel indicate IgK light chain restriction (IgK/IgL > 5.5) and IgL light chain restriction (IgK/IgL < 0.7), respectively. BCG, Bacillus Calmette–Guérin; N.S., not significant; FFPE, formalin-fixed, paraffin-embedded; HIC, Hunner-type interstitial cystitis; HIC-L, Hunner lesion of Hunner-type interstitial cystitis; HIC-NL, non-Hunner lesion of Hunner-type interstitial cystitis.

Article Snippet: In brief, the FFPE section was stained using a Human Maxpar Immuno-Oncology Imaging Mass Cytometry Panel Kit (#201508; Fluidigm, South San Francisco, CA, USA) and 141Pr-CD38 (#3141018D; Fluidigm), following the manufacturer’s protocol.

Techniques: Clinical Proteomics, Staining, Mass Cytometry

Journal: eLife

Article Title: Single-cell glycomics analysis by CyTOF-Lec reveals glycan features defining cells differentially susceptible to HIV

doi: 10.7554/eLife.78870

Figure Lengend Snippet: ( A ) Histograms showing the expression of activation markers on CD4+ Tm cells from resting (blue) and PHA-stimulated PBMCs (red). One of four representative donors is shown. ( B ) Stimulated CD4+ Tm cells express more sialic acid than resting CD4+ Tm cells do. Shown are the four PBMC donors. ( C ) HLADR High , CD69 High , CD38 High , CD38 High , CD25 High , CD28 High , and ICOS High CD4+ Tm cells bind more WGA than CD4+ Tm cells expressing low levels of these activation markers. Shown are the four PBMC donors. For panels B–C, *p<0.05, **p<0.01 as assessed using the Student’s paired t test and adjusted for multiple testing using the Benjamini-Hochberg for false discovery rate (FDR). ( C ) Treatment with the sialic acid synthase inhibitor P-3FZX-Neu5Ac does not decrease cell-surface levels of sialidase on CD4 + T cells. PBMCs were treated for 24 hr with the indicated concentrations of P-3FZX-Neu5Ac prior to assessment of cell-surface WGA binding. Shown are overlaid histograms demonstrating no decrease in cell-surface sialic acid levels (as reflected by WGA binding) in the inhibitor-treated cells. Results are gated on live, singlet CD3+ CD8- CD4+ cells. Numbers correspond to percent of cells within the indicated gate.

Article Snippet: Antibody , Anti-Human CD38 (HIT2) (Mouse, Monoclonal) , Fluidigm , Cat# 3172007B , CyTOF (1:200).

Techniques: Expressing, Activation Assay, Binding Assay

Journal: eLife

Article Title: Single-cell glycomics analysis by CyTOF-Lec reveals glycan features defining cells differentially susceptible to HIV

doi: 10.7554/eLife.78870

Figure Lengend Snippet:

Article Snippet: Antibody , Anti-Human CD38 (HIT2) (Mouse, Monoclonal) , Fluidigm , Cat# 3172007B , CyTOF (1:200).

Techniques: Recombinant, Plasmid Preparation, Software